公开(公告)号：EP1389611B1

公开(公告)日：2012-06-27

申请号：EP02722849.3

申请日：2002-04-26

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： SATO, Masakazu ,  MIYATA, Noriyuki ,  ISHII, Takaaki ,  MATSUNAGA, Yuko ,  AMADA, Hideaki

IPC分类号： A61K31/4418 ,  A61K31/4525 ,  A61K31/47 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/55 ,  A61P3/10 ,  C07C259/14 ,  C07D207/20 ,  C07D211/70 ,  C07D213/74 ,  C07D215/06 ,  C07D241/04 ,  C07D265/30 ,  C07D491/113 ,  C07D217/04 ,  C07D213/75 ,  C07D401/04 ,  C07D491/10 ,  C07D295/15

CPC分类号： C07D213/75 ,  A61K31/136 ,  A61K31/402 ,  A61K31/4418 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/47 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/54 ,  A61K31/55 ,  C07C259/14 ,  C07D207/20 ,  C07D211/22 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D211/70 ,  C07D213/74 ,  C07D217/04 ,  C07D295/13 ,  C07D295/135 ,  C07D295/15 ,  C07D401/04 ,  C07D491/10

摘要： Hydroxyformamidine compounds represented by the following general formula or pharmaceutically acceptable salts thereof: wherein R1 represents substituted morpholino, substituted piperidino, piperazin-1-yl, substituted piperazin-1-yl, thiomorpholin-1-yl, perhydroazepin-1-yl, perhydroazocin-1-yl, tetrahydropyridin-1-yl, pyrrolin-1-yl, etc.; X represents nitrogen or CR5; and R2 to R5 are the same or different and each represents hydrogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl or halogeno. Drugs inhibiting 20-HETE synthase relating to contraction/dilation of microvessels, induction of cell proliferation, etc. in main organs such as kidney and cerebral vessels.